U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.

  • Product Code
  • ILEA001224080
  • Registered date
  • 2023/1/07 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2023 Kyodo News
  • Media size
  • 2806 × 3727 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 463.54(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Oracle to invest $8 bil. in Japan

    Oracle to invest $8 bil. in Japan

    U.S. IT firm Oracle Corp. CEO Safra Catz holds a press conference in Tokyo on April 18, 2024. She said the Japanese unit of Oracle Corp. will invest $8 billion in Japan over the next 10 years to respond to the country's growing demand for cloud computing and artificial intelligence.
      Oracle to invest $8 bil. in Japan

      Oracle to invest $8 bil. in Japan

      U.S. IT firm Oracle Corp. CEO Safra Catz holds a press conference in Tokyo on April 18, 2024. She said the Japanese unit of Oracle Corp. will invest $8 billion in Japan over the next 10 years to respond to the country's growing demand for cloud computing and artificial intelligence.

        Sompo CEO to step down over Bigmotor insurance fraud scandal

        TOKYO, Japan, Jan. 26 Kyodo - Major Japanese insurance firm Sompo Holdings Inc. CEO Kengo Sakurada holds a press conference in Tokyo on Jan. 26, 2024, to announce he will step down at the end of March to take responsibility for the company's involvement in used car dealer Bigmotor Co.'s insurance fraud scandal. (Kyodo)
          Sompo CEO to step down over Bigmotor insurance fraud scandal

          Sompo CEO to step down over Bigmotor insurance fraud scandal

          Major Japanese insurance firm Sompo Holdings Inc. CEO Kengo Sakurada holds a press conference in Tokyo on Jan. 26, 2024, to announce he will step down at the end of March to take responsibility for the company's involvement in used car dealer Bigmotor Co.'s insurance fraud scandal.
            Sompo CEO to step down over Bigmotor insurance fraud scandal

            Sompo CEO to step down over Bigmotor insurance fraud scandal

            Major Japanese insurance firm Sompo Holdings Inc. CEO Kengo Sakurada holds a press conference in Tokyo on Jan. 26, 2024, to announce he will step down at the end of March to take responsibility for the company's involvement in used car dealer Bigmotor Co.'s insurance fraud scandal.
              Sompo CEO to step down over Bigmotor insurance fraud scandal

              Sompo CEO to step down over Bigmotor insurance fraud scandal

              Major Japanese insurance firm Sompo Holdings Inc. CEO Kengo Sakurada holds a press conference in Tokyo on Jan. 26, 2024, to announce he will step down at the end of March to take responsibility for the company's involvement in used car dealer Bigmotor Co.'s insurance fraud scandal.
                Sompo CEO to step down over Bigmotor insurance fraud scandal

                Sompo CEO to step down over Bigmotor insurance fraud scandal

                Major Japanese insurance firm Sompo Holdings Inc. CEO Kengo Sakurada (R) bows at a press conference in Tokyo on Jan. 26, 2024, and announces he intends to step down at the end of March to take responsibility for the company's involvement in used car dealer Bigmotor Co.'s insurance fraud scandal.
                  Rekanemab NHI drug price listing Eisai press conference

                  Rekanemab NHI drug price listing Eisai press conference

                  Rekanemab NHI drug price listing Eisai press conference. Haruo Naito, Representative Executive Officer and CEO of Eisai Co.=Date:December 13, 2023, Place:Tokyo
                    Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

                    Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

                    Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo
                      Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

                      Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease Press Conference

                      Eisai Receives Official U.S. FDA Approval for Recanemab for the Treatment of Alzheimer's Disease. Photo shows Haruo Naito, Eisai Representative Executive Officer, at the press conference.=Date:July 7, 2023,Place:Tokyo